408 related articles for article (PubMed ID: 16673804)
1. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
Beutner K; Chakrabarty A; Lemke S; Yu K
J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
Jarratt MT; Clark SD; Savin RC; Swinyer LJ; Safley CF; Brodell RT; Yu K
Cutis; 2006 Nov; 78(5):348-54. PubMed ID: 17186795
[TBL] [Abstract][Full Text] [Related]
3. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
[TBL] [Abstract][Full Text] [Related]
4. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
Sofen H; Hudson CP; Cook-Bolden FE; Preston N; Colón LE; Colón LE; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2011 Aug; 10(8):885-92. PubMed ID: 21818510
[TBL] [Abstract][Full Text] [Related]
5. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
6. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
[TBL] [Abstract][Full Text] [Related]
7. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
Jarratt M; Breneman D; Gottlieb AB; Poulin Y; Liu Y; Foley V
J Drugs Dermatol; 2004; 3(4):367-73. PubMed ID: 15303780
[TBL] [Abstract][Full Text] [Related]
8. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
9. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial.
Vena GA; Cassano N; D'Argento V; Milani M
Br J Dermatol; 2006 Feb; 154(2):353-6. PubMed ID: 16433809
[TBL] [Abstract][Full Text] [Related]
10. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB; Gold MH; Zib B; Davis MW;
J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
[TBL] [Abstract][Full Text] [Related]
11. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis.
Mraz S; Leonardi C; Colón LE; Johnson LA
J Dermatolog Treat; 2008; 19(6):354-9. PubMed ID: 18923991
[TBL] [Abstract][Full Text] [Related]
12. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
13. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.
Lowe N; Feldman SR; Sherer D; Weiss J; Shavin JS; Lin YL; Foley V; Soto P
J Dermatolog Treat; 2005 Aug; 16(3):158-64. PubMed ID: 16096182
[TBL] [Abstract][Full Text] [Related]
14. Improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray.
Brodell R; Preston N
J Drugs Dermatol; 2012 Dec; 11(12):1455-9. PubMed ID: 23377516
[TBL] [Abstract][Full Text] [Related]
15. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis.
Poulin Y; Papp K; Bissonnette R; Barber K; Kerrouche N; Villemagne H;
J Dermatolog Treat; 2010 May; 21(3):185-92. PubMed ID: 20131980
[TBL] [Abstract][Full Text] [Related]
16. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis.
Menter A
Cutis; 2012 Feb; 89(2):89-94. PubMed ID: 22474733
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
18. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
Decroix J; Pres H; Tsankov N; Poncet M; Arsonnaud S
Cutis; 2004 Sep; 74(3):201-6. PubMed ID: 15499763
[TBL] [Abstract][Full Text] [Related]
19. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
Jorizzo JL; Magee K; Stewart DM; Lebwohl MG; Rajagopalan R; Brown JJ
Cutis; 1997 Jul; 60(1):55-60. PubMed ID: 9252738
[TBL] [Abstract][Full Text] [Related]
20. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial.
Menter A
Cutis; 2007 Nov; 80(5 Suppl):12-9. PubMed ID: 18154219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]